Skip to main content
Clinical Trials/IRCT20150101020514N8
IRCT20150101020514N8
Recruiting
Phase 2

Comparative evaluation of the safety and efficacy of botulinum toxin type A (product of Imen Vaccine Alborz CO) in comparison with Dysport (standard treatment) for treating glabellar rhytids in people with moderate to severe glabellar rhytids.

Imen vaccine alborz Company0 sites140 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
skin rejuvenation.
Sponsor
Imen vaccine alborz Company
Enrollment
140
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Imen vaccine alborz Company

Eligibility Criteria

Inclusion Criteria

  • Men and women with 18 to 75 years old
  • mild to moderate Glabellar Lines
  • signing informed consent form

Exclusion Criteria

  • Hypersensitivity to botulinum toxin or other components of formulation
  • History of treatment with botulinum toxin in face area within the past 6 months
  • History of using aminoglycosides, penicillin, kinin, chloroquine,Calcium Channel Blockers, warfarin and aspirin
  • History of injectable filler, chemical peels and laser treatment of any type within the past year
  • Significant scarring ,skin disorder or wound infection in the facial area
  • Neuro\-muscular disorders like miastenia gravis, iron lambert , ALS
  • Significant face asymmetry
  • Any active, chronic and recurrent infection
  • Pregnancy/ breast feeding

Outcomes

Primary Outcomes

Not specified

Similar Trials